Compounds > phenyl acetate
Page last updated: 2024-08-23

phenyl acetate and Graft vs Host Disease

phenyl acetate has been researched along with Graft vs Host Disease in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19903 (27.27)18.7374
1990's0 (0.00)18.2507
2000's2 (18.18)29.6817
2010's1 (9.09)24.3611
2020's5 (45.45)2.80

Authors

AuthorsStudies
Assanelli, AA; Bernardi, M; Bruno, A; Carrabba, MG; Ciceri, F; Clerici, D; Corti, C; Farina, F; Giglio, F; Greco, R; Guggiari, E; Lazzari, L; Lorentino, F; Lunghi, F; Lupo-Stanghellini, MT; Marcatti, M; Marktel, S; Mastaglio, S; Peccatori, J; Piemontese, S; Ruggeri, A; Xue, E1
Babushok, D; Carulli, A; Frey, NV; Freyer, CW; Ganetsky, A; Gier, S; Gill, SI; Hexner, EO; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, K; Schuster, M; Smith, J; Stadtmauer, EA; Timlin, C1
Hosoi, H; Murata, S; Mushino, T; Nishikawa, A; Sonoki, T1
Abramova, R; Assal, A; Bansal, R; Gordillo, CA; Mapara, MY; Pereira, MR; Reshef, R1
Cho, C; DeRespiris, L; Devlin, SM; Figgins, B; Flynn, J; Giralt, SA; Griffin, M; Jakubowski, AA; Lau, C; Lin, A; Papadopoulos, EB; Perales, MA; Proli, A; Seo, SK; Shaffer, B; Tamari, R1
Benesch, M; Donnerer, J; Kubesch, K; Lackner, H; Schwinger, W; Sperl, D; Strenger, V; Zach, K1
MARK, R; SCHLESINGER, M1
Bolaños-Meade, J; Vogelsang, GB1
Avgil, M; Avraham, A; Bitan, M; Gesundheit, B; Or, R; Resnick, I; Sacks, Z; Shapira, MY1
Khaitov, RM; Manyko, VM; Petrov, RV; Seslavina, LS1
Coscia, A; Winick, M1

Trials

1 trial(s) available for phenyl acetate and Graft vs Host Disease

ArticleYear
Montelukast in chronic graft-versus-host disease: a breath of fresh air?
    Transplantation, 2007, Mar-15, Volume: 83, Issue:5

    Topics: Acetates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Disease; Cyclopropanes; Graft vs Host Disease; Humans; Leukotriene Antagonists; Pilot Projects; Quinolines; Sulfides

2007

Other Studies

10 other study(ies) available for phenyl acetate and Graft vs Host Disease

ArticleYear
Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation.
    Blood advances, 2022, 05-24, Volume: 6, Issue:10

    Topics: Acetates; Calcineurin Inhibitors; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines

2022
Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.
    Leukemia & lymphoma, 2022, Volume: 63, Issue:8

    Topics: Acetates; Adult; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies; Unrelated Donors; Valacyclovir

2022
Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.
    Annals of hematology, 2020, Volume: 99, Issue:10

    Topics: Acetates; Adult; Aged; Allografts; Antiviral Agents; Case-Control Studies; Cytomegalovirus Infections; Eosinophilia; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Quinazolines; Transplantation Conditioning

2020
Extended letermovir administration, beyond day 100, is effective for CMV prophylaxis in patients with graft versus host disease.
    Transplant infectious disease : an official journal of the Transplantation Society, 2021, Volume: 23, Issue:2

    Topics: Acetates; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines; Retrospective Studies

2021
Letermovir for Prevention of Cytomegalovirus Reactivation in Haploidentical and Mismatched Adult Donor Allogeneic Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:1

    Topics: Acetates; Adult; Cyclophosphamide; Cytomegalovirus; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Quinazolines

2021
Letermovir in paediatric HSCT recipients.
    The Journal of antimicrobial chemotherapy, 2019, 09-01, Volume: 74, Issue:9

    Topics: Acetates; Antiviral Agents; Child; Cytomegalovirus Infections; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Liver Diseases; Quinazolines; Transplant Recipients

2019
WASTING DISEASE INDUCED IN YOUNG MICE BY ADMINISTRATION OF CORTISOL ACETATE.
    Science (New York, N.Y.), 1964, Feb-28, Volume: 143, Issue:3609

    Topics: Acetates; Animals; Cachexia; Graft vs Host Disease; Hydrocortisone; Metabolic Diseases; Mice; Research; Toxicology; Wasting Syndrome

1964
Sparing effect by montelukast treatment for chronic graft versus host disease: a pilot study.
    Transplantation, 2007, Mar-15, Volume: 83, Issue:5

    Topics: Acetates; Administration, Oral; Adolescent; Adult; Chronic Disease; Cyclopropanes; Female; Graft vs Host Disease; Humans; Leukotriene Antagonists; Male; Middle Aged; Pilot Projects; Quinolines; Retrospective Studies; Sulfides; Treatment Outcome

2007
A new quantitative GVH assay: simultaneous estimation of mitostatic and lymphotoxic effects of immunosuppressants.
    Transplantation proceedings, 1971, Volume: 3, Issue:1

    Topics: Acetates; Animals; Cyclophosphamide; Cytotoxicity Tests, Immunologic; Graft vs Host Disease; Graft vs Host Reaction; Hydrocortisone; Immunosuppression Therapy; Lymph Nodes; Lymphocytes; Mice; Mitosis; Radiation Injuries, Experimental; Transplantation Immunology; Transplantation, Homologous

1971
Cortisone-induced growth failure in neonatal rats.
    Pediatric research, 1968, Volume: 2, Issue:6

    Topics: Acetates; Animals; Animals, Newborn; Body Weight; Cortisone; DNA; Female; Graft vs Host Disease; Injections, Subcutaneous; Organ Size; Pregnancy; Proteins; Rats; Regeneration; RNA; Spleen; Thymus Gland

1968